Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall

Abstract

Rationale: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC. Patient concerns: We reported a 49-year-old woman presenting with a giant breast tumor. Diagnoses: Stage IV TNBC with chest wall metastasis. Interventions: The patient underwent long-term use of bevacizumab combined with chemotherapy. Outcomes: The patient was on follow-up for 46 months, a remarkable improvement of the chest wall cutaneous lesion was observed. Lessons: Bevacizumab may provide benefits for TNBC patients with chest wall metastasis.